Cingulate Inc. (CING) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US17248W3034
Cingulate Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -19.94 m USD |
| EBIT | -21.55 m USD |
| Net income | -22.45 m USD |
| Diluted EPS – continuing operations | -4.44 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Cingulate Inc.
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
More stocks
- Fatpipe Inc/UT (FATN)
- Adex Mining Inc (ADE.V)
- Great Elm Group, Inc. (GEG)
- MedFirst Healthcare Services lnc (4175.TWO)
- Infas Holding AG (IFS.F)
- Groupe LDLC SA (ALLDL.PA)
- CHEGG, INC (CHGG)
- ASTA Corporation (246720.KQ)
- U&I Corporation (056090.KQ)
- Microtips Technology (3285.TWO)
- QUANTUM X LABS INC. (QXL)
- Garo AB (GARO.ST)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.